<DOC>
	<DOCNO>NCT00571428</DOCNO>
	<brief_summary>To evaluate efficacy safety arformoterol tartrate inhalation solution 30μg/4mL QD ( two 15μg/2mL dosed combination ) 24-hour period compare arformoterol tartrate inhalation solution 15μg/2 mL BID subject COPD .</brief_summary>
	<brief_title>Efficacy Safety Study Arformoterol QD Dosing Versus BID Dosing COPD</brief_title>
	<detailed_description>This modify blind , randomize , multicenter , single dose two-way crossover study assess efficacy safety arformoterol 15μg BID versus arformoterol 30μg QD subject COPD . Subject participation last approximately three week include screen visit , two 24-hour visit , follow telephone call . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male female subject must least 45 year old time consent . Subjects must preestablished primary clinical diagnosis COPD . Subjects must baseline FEV1 ≤ 65 % predict normal value Visit 1 . Subjects must FEV1 ≥ 0.70L Visit 1 . Subjects must FEV1/forced vital capacity ( FVC ) ratio ≤ 70 % Visit 1 . Subjects 15 packyear smoke history baseline breathlessness severity grade 2 ( measure Modified Medical Research Council [ MMRC ] Dyspnea Scale Score ) Screening . Subjects lifethreatening/unstable respiratory status , include upper low respiratory tract infection , within previous 30 day prior Visit</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Emphysema</keyword>
</DOC>